BETA Technologies launches IPO of 25 million shares priced $27-$33
Patrick R. O’Neil, Executive Vice President, CLO & General Counsel at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 90,400 shares of common stock on September 2nd and 3rd, 2025. The sales, executed in multiple transactions, fetched prices ranging from $54.5148 to $61.42, resulting in total proceeds of approximately $5.39 million.
The sales were related to the exercise of stock options. O’Neil exercised options to acquire a total of 89,900 shares at prices ranging from $32.6 to $53.77, for a total value of $4,054,726.
Following these transactions, O’Neil directly owns 7,330 shares of Ionis Pharmaceuticals. Get deeper insights into insider trading patterns and 12 additional ProTips with an InvestingPro subscription.
In other recent news, Ionis Pharmaceuticals has reported positive outcomes from its Phase 3 CORE and CORE2 trials for its triglyceride drug, leading to a significant 32% increase in its stock following the announcement. The trials showed notable benefits, including triglyceride lowering and reduced risk of acute pancreatitis, which were described by Bernstein SocGen Group as exceeding high expectations. As a result, several analyst firms have adjusted their outlooks. RBC Capital raised its price target for Ionis Pharmaceuticals to $80, maintaining an Outperform rating due to promising Phase III data for its acute pancreatitis treatment. Similarly, H.C. Wainwright increased its price target to $95, citing strong triglyceride reductions in pivotal studies. Additionally, BMO Capital upgraded the company from Market Perform to Outperform, acknowledging the blockbuster potential of Olezarsen. Oppenheimer also raised its price target to $81, following the announcement of successful trial results for Tryngolza (olezarsen) in treating severe hypertriglyceridemia. These developments highlight the growing confidence in Ionis Pharmaceuticals’ therapeutic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.